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ABSTRACT Regulated erroneous protein translation (adaptive mistranslation) in-
creases proteome diversity and produces advantageous phenotypic variability in the
human pathogen Candida albicans. It also increases ﬁtness in the presence of ﬂu-
conazole, but the underlying molecular mechanism is not understood. To address
this question, we evolved hypermistranslating and wild-type strains in the absence
and presence of ﬂuconazole and compared their ﬂuconazole tolerance and resis-
tance trajectories during evolution. The data show that mistranslation increases tol-
erance and accelerates the acquisition of resistance to ﬂuconazole. Genome se-
quencing, array-based comparative genome analysis, and gene expression proﬁling
revealed that during the course of evolution in ﬂuconazole, the range of mutational
and gene deregulation differences was distinctively different and broader in the hy-
permistranslating strain, including multiple chromosome duplications, partial chro-
mosome deletions, and polyploidy. Especially, the increased accumulation of loss-of-
heterozygosity events, aneuploidy, translational and cell surface modiﬁcations, and
differences in drug efﬂux seem to mediate more rapid drug resistance acquisition
under mistranslation. Our observations support a pivotal role for adaptive mistrans-
lation in the evolution of drug resistance in C. albicans.
IMPORTANCE Infectious diseases caused by drug-resistant fungi are an increasing
threat to public health because of the high mortality rates and high costs associated
with treatment. Thus, understanding of the molecular mechanisms of drug resis-
tance is of crucial interest for the medical community. Here we investigated the role
of regulated protein mistranslation, a characteristic mechanism used by C. albicans
to diversify its proteome, in the evolution of ﬂuconazole resistance. Such codon am-
biguity is usually considered highly deleterious, yet recent studies found that mis-
translation can boost adaptation in stressful environments. Our data reveal that CUG
ambiguity diversiﬁes the genome in multiple ways and that the full spectrum of
drug resistance mechanisms in C. albicans goes beyond the traditional pathways
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that either regulate drug efﬂux or alter the interactions of drugs with their targets.
The present work opens new avenues to understand the molecular and genetic ba-
sis of microbial drug resistance.
KEYWORDS Candida albicans, ﬂuconazole, LOH, aneuploidy, codon ambiguity, drug
resistance evolution, phenotypic variability, protein mistranslation
Fungal infections are an increasingly serious health problem because of immunedeﬁciencies caused by diseases like HIV/AIDS and cancer therapies, as well as
prolonged antibiotic treatments (1). Deep-seated and disseminated infections are
difﬁcult and extremely costly to treat and are normally associated with high mortality
rates. In the United States alone, the costs of antifungal therapy have reached $8
billion/annum (2). Resistance to the commonly used azoles is increasing, and alternative
antifungals, such as encapsulated amphotericin B or echinocandins, are expensive and
increase the cost of antifungal therapy dramatically.
Antifungal resistance has been studied intensively and involves DNA mutations,
genome plasticity, cell signaling, and gene expression alterations (3–5). In the speciﬁc
case of azoles, resistance is due mainly to mutations in the ergosterol biosynthesis
pathway targeted by the drug and drug efﬂux. Lanosterol 14-demethylase (encoded
by ERG11) is a key enzyme in the ergosterol biosynthesis pathway and the direct target
of azole antifungals. Overexpression of UPC2, the transcription factor regulating ERG11,
or aneuploidy events that increase the ERG11 copy number lead to increased azole
resistance (6, 7). Gain-of-function mutations in TAC1 and MRR1 (7, 8), transcription
factors that positively regulate the transcription of efﬂux pumps encoded by the
CDR1/CDR2 or MDR1 genes (5, 9), also result in increased drug resistance. Types of
mutations that result in acquired resistance include genome rearrangements, protein
sequence changes (4, 5), aneuploidy and loss of heterozygosity (LOH) (6, 10–13), and
increased mutagenesis due to loss of mismatch repair or elevated levels of DNA
double-strand break repair (3).
Candida albicans, the most prevalent pathogen of humans, has a unique codon
usage system whereby translational ﬁdelity is modulated by environmental cues (14).
A mutant serine tRNA is recognized and aminoacylated by both leucyl- and seryl-tRNA
synthetases (LeuRS and SerRS, respectively) (15), yielding a charged tRNA that can
incorporate either Leu or Ser at CUG codons. This leads to proteome-wide plasticity,
such that each protein in the cell is represented by a mixture of polypeptides contain-
ing Ser or Leu at such sites. The basal level of Ser and Leu incorporated at CUG sites (3%
leucine and 97% serine in rich medium) differs in different ecological niches and under
different environmental conditions, contributing to proteomic and phenotypic diver-
siﬁcation (16). In a previous study, we increased Leu misincorporation at CUG sites to
22% by inserting a copy of a yeast Leu tDNACAGLeu gene into the genome of C. albicans
strain SN148 and could show that this strain was slightly more tolerant to ﬂuconazole
than the wild-type (WT) strain when grown on solid agar plates containing this
antifungal (16). This result suggested that CUG mistranslation might have a role in
antifungal drug tolerance. However, the underlying molecular mechanism by which
proteomic plasticity results in ﬂuconazole resistance is unknown. As mistranslation is
associated with antibiotic resistance in bacteria (17–19), we hypothesized that it may
also be relevant to the evolution of ﬂuconazole resistance in C. albicans.
In the present study, we investigated how CUG mistranslation contributes to the
acquisition of ﬂuconazole resistance by evolving WT and hypermistranslating strains of
C. albicans in parallel in the absence and presence of ﬂuconazole. These strains were
then characterized by genome resequencing, array-based comparative genome hybrid-
ization (CGH), and gene expression analysis. We found that mistranslation accelerated
the acquisition of ﬂuconazole resistance in C. albicans and revealed a number of
genomic features and key genes that provide insights into how CUG mistranslation
promotes resistance to ﬂuconazole.
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RESULTS
To clarify the role of mistranslation in ﬂuconazole resistance, we used C. albicans
strains that incorporate Leu at CUG sites at different levels; a control strain (T0)
incorporates the WT levels of 3% Leu and 97% Ser, and a hypermistranslating strain (T1)
incorporates 22 and 78% Leu and Ser at the same sites, respectively (16). We asked
initially if mistranslation alters the frequency of acquisition of ﬂuconazole resistance
during evolution. For this, strains T0 and T1 were evolved by serial passage in increasing
concentrations of ﬂuconazole (Fig. 1; see Fig. S1 in the supplemental material) and
genetically tested at three different time points, i.e., at the beginning of the experiment
(no ﬂuconazole, no sufﬁx), at medium ﬂuconazole concentrations (16 to 32 g/ml,
sufﬁx FM), and at a high ﬂuconazole concentration (256 g/ml, sufﬁx FH) (Fig. 1;
Fig. S1). Both strains were also evolved in the absence of ﬂuconazole to test for effects
due to mistranslation alone (sufﬁx NF).
When evolved without ﬂuconazole, the T0NF and T1NF strains did not exhibit a
visible difference in resistance (Fig. 1, green and gray lines). In contrast, the evolution
of either strain T0 or T1 in the presence of ﬂuconazole resulted in the acquisition of
high-level resistance (MIC of 256 g/ml) during evolution with no difference in the
mutation rate, albeit with a marked difference in the speed of acquisition. The hyper-
mistranslating T1 strain became resistant (T1FH, MIC of 256 g/ml) within 10 days of
passaging (~2 days per passage), while control strain T0 began to show increased
resistance after 1 week of evolution (T0FM) and reached a MIC of 256 g/ml (T0FH) after
1 month of passaging (Fig. 1). Thus, increased levels of mistranslation appeared to
speed up the emergence of ﬂuconazole resistance. To address the generality of this
phenomenon, we asked if mistranslation also promotes resistance to caspofungin, an
antifungal drug of clinical relevance belonging to the echinocandin class. While the
MICs for both strains T0 and T1 were in the same range (0.094 to 0.125 g/ml), only the
T1 hypermistranslating strain produced microcolonies within the entire inhibition
ellipse of the E test. These microcolonies also grew in liquid medium containing
caspofungin concentrations of up to 32 g/ml (Fig. S2).
Differences in resistance to ﬂuconazole. To clarify how resistance to ﬂuconazole
evolved in both strains T0 and T1, we resequenced the genomes of the evolved strains
by using the Illumina sequencing platform and analyzed gene expression with the
Agilent DNA microarray platform. The T0 strain acquired a known gain-of-function
mutation (V877F) in transcription factor MRR1 (20), a positive transcriptional regulator
FIG 1 Fluconazole resistance proﬁles during evolution. (A) During evolution with ﬂuconazole (FLZ), control strain
TO (3.2% natural mistranslation; blue line) and hypermistranslating strain T1 (22.5% leucine misincorporation; red
line) showed increased resistance to the drug over time yet revealed marked differences in the speed of resistance
acquisition. Both strains evolved without (w/o) the drug (green and gray lines) did not show increased resistance.
(B) E tests after 10 days of evolution. Hypermistranslating strain T1 rapidly adapted to the drug and showed
complete resistance to ﬂuconazole, while WT strain T0 was still sensitive.
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of the multidrug efﬂux pump gene MDR1; consistent with this, MDR1 expression was
upregulated 5.3-fold (Table S1; Fig. S3). The hypermistranslating T1 strain was remark-
ably different; it acquired a previously described A736V gain-of-function mutation in
the transcriptional activator TAC1, which drives high levels of expression of the CDR1
and CDR2 genes, which encode the ABC transporters (21) (CDR1, 4.8-fold; CDR2, 3.9-fold;
Table S1; Fig. S3). Analysis of the genomic DNA revealed LOH of ERG11, the target of
ﬂuconazole, in T1FM and T1FH; no such LOH event was observed in T0FM and T0FH. In
addition, a previously unknown mutation (S35C) in the oxidosqualene cyclase gene
ERG7 was also detected in T0FM, T0FH, and T1FM (Table S1). Moreover, the expression
of genes encoding components of the ergosterol biosynthesis pathway, the molecular
target of ﬂuconazole, were upregulated in both T0 and T1 ﬂuconazole-resistant strains
(Fig. S3). Taken together, these results suggest that both strains activated the common
mechanisms of azole resistance, yet they did so via different drug efﬂux pathways and
through different types of genomic alterations.
Genomic alterations induced by mistranslation and ﬂuconazole. A combination
of whole-genome sequencing (WGS) and high-density array-based CGH data analysis
provided deeper insight into the role of mistranslation in genome evolution.
By comparing genotype changes that were heterozygous in the nonevolved control
strain and homozygous in the other samples analyzed, we found that strain T0
accumulated a moderate number of such events (500) during evolution, regardless of
whether ﬂuconazole was present (T0FM and T0FH) or absent (T0NF). In contrast, the
hypermistranslator T1 accumulated 2,193 LOH events during evolution in the absence
of ﬂuconazole (T1NF) and5,100 LOH events in the presence of ﬂuconazole (T1FM and
T1FH). Thus, mistranslation alone resulted in the accumulation of a higher number of
LOH events during evolution and the combination of mistranslation and ﬂuconazole
(strain T1) more than doubled the number of LOH events. Interestingly, in the resistant
T1FH strain, a small group of open reading frames were especially rich in such LOH
events, with orf19.2850 (yeast ortholog involved in telomeric silencing), MEC1 (encodes
a cell cycle checkpoint protein with a role in genome integrity), HAL9 (yeast ortholog
involved in salt tolerance), and INT1 (has a role in morphogenesis and adhesion) having
more than 51 LOH events (median, 5 LOH events).
Further, the evolution of the hypermistranslating T1 strain resulted in the appear-
ance of two large LOH regions that include most of the above-mentioned events. A
large LOH region on chromosome 5 (Chr5) appeared exclusively in the presence of
ﬂuconazole (T1FM and T1FH), while an LOH tract in the left arm of ChrR appeared
regardless of drug treatment (T1NF, T1FM, and T1FH) (Fig. S4), suggesting that it was
already present in the parental T1 strain or that it occurs at a recombination hotspot.
Notably, in both LOH regions, several loci encoding aminoacyl-tRNA synthetases
and tRNA modiﬁcation enzymes lost heterozygosity in strain T1 during evolution. We
observed homozygosis of the cytosolic leucyl-tRNA synthetase gene locus (LeuRS;
CDC60, ChrR) regardless of drug treatment. LeuRS charges the atypical tRNACAGSer
with leucine and is central to Leu/Ser ambiguity in mistranslation in C. albicans (22).
Similar LOH events during evolution of strain T1 involved loci encoding the
mitochondrial (MSM1) and cytosolic (MES1) methionyl-tRNA synthetases; the mito-
chondrial tryptophanyl-tRNA synthetase (MSW1); and the cytosolic phenylalanyl
(FRS1)-, putative prolyl (PRS)-, putative aspartyl (DPS1-1)-, and tryptophanyl (WRS1)-
tRNA synthetases; as well as orf19.3956 (orthologs have glutaminyl-tRNA synthase
activity), orf19.2387 (a putative tRNA-Pro synthetase), and orf19.2382 (protein similar to
isoleucyl-tRNA synthetase). Apart from WRS1 (Chr1), these genes are all located within
the LOH regions of ChrR and Chr5, suggesting that the tRNA aminoacylation system
might be a driving force for the LOH on those chromosomes (Fig. 2; Fig. S4).
Since LOH events on Chr5 appear frequently in ﬂuconazole-resistant C. albicans
isolates (10), these data support the idea that mistranslation, LOH of Chr5, and
ﬂuconazole resistance are linked. To determine if genes affected by LOH events during
evolution were selected because of their serine codon usage, we computed the relative
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synonymous codon usage (RSCU) of the seven serine codons of strains T1 and T1FH in
all genes (with Anaconda [23]) and compared the two sets codon by codon. We found
statistically signiﬁcant differences in UCA, UCC, and UCG usage, which was decreased
in the LOH-affected genes of the nonevolved T1 strain, and in UCG usage, which was
decreased in the LOH-affected genes of T1FH (Table S2A).
Interestingly, the number of CUG codons differs between alleles (a and b) of genes
that lost heterozygosity in T1FH (Table S2B); genes with a positive difference (a  b)
underwent a reduction in the number of CTG codons, and genes with a negative
difference (a  b) had an increase in the number of CTG codons. This suggests that the
loss of one allele (Table S2B) had a balancing effect on the number of CTG codons.
As mentioned above, the LOH in the left arm of ChrR was present in all evolved T1
clones, regardless of whether cells were untreated (T1NF) or treated (T1FM and T1FH)
with ﬂuconazole (Fig. S4). The results imply that homozygosis in this region was already
present as a standing variation in the starting population and was likely selected
because of the presence of genes that are important in overcoming the potentially
lethal effect of increased mistranslation. Because of their immediate availability and
higher initial frequency, this standing variation (beneﬁcial alleles) may speed up
adaptation to new environments if compared to the time required for new beneﬁcial
mutations to arise (24). This LOH region on ChrR is enriched in genes with gene
ontology (GO) terms related to peptide transport, cellular and nucleic acid metabolic
processes, chromatin silencing at telomeres, and tRNA aminoacylation (Table S3). Of
note, genes involved in transcriptional silencing by heterochromatin and aminoacyla-
tion were enriched among genes with sequence changes, and they represent two
critical steps required for the accurate transfer of genetic information, a feature of
particular importance under increased mistranslation.
Copy number variation upon ﬂuconazole exposure. WGS revealed that the
evolution of strain T1 in the presence of ﬂuconazole also led to loss of chromosomal
repeat regions in Chr6, Chr4, and Chr2 and of a few telomere-proximal genes (e.g.,
CTA24, RRN3, TLO5). Furthermore, it showed that evolution of strain T1 in the presence
of ﬂuconazole was accompanied by the apparent gain and loss of regions of Chr1, Chr4,
Chr5, and ChrR. Speciﬁcally, T1FM had increased copies of Chr1 (164001 to 168200),
Chr4 (46800 to 47200 and 518001 to 530000), Chr5 (744001 to 752000 and 860001 to
876000), and ChrR (1884001 to 1898000). Within these ampliﬁed chromosomal regions
were, apart from the genes of the rDNA locus and repeat regions of Chr1, genes
functioning in the regulation of transcription. Many of the ampliﬁed genome regions in
strain T1FM were not detectable at the end of evolution in the presence of ﬂuconazole.
Rather, T1FH showed gains almost exclusively on Chr7 (150001 to 170000, 262001 to
328000, 318001 to 324000, 360001 to 380000, and 482001 to 576000), mainly located
in the region between WHI3 and MRS7b. The RSCU for serine codons in genes affected
FIG 2 YMAP visualization of SNP-CGH data for three T1FH clones. The copy numbers and SNP-allele ratios of all three T1FH
samples were visualized with YMAP (49). Changes in the copy number estimate for regions relative to the parental strain are
illustrated by dark bars drawn up- or downward, depending on the direction and magnitude of the change. These strains
appear to be tetraploid on the basis of the copy number estimates for Chr7 (and most of ChrR in clone T1FHb), which are 3/4
of the other chromosomes. Color illustrates SNP status across regions. Heterozygous regions are gray, white regions do not
have SNPs in the SC5314 reference sequence, and cyan is homozygous “a” alleles (e.g., aaaa on Chr5 in all three clones and
ChrR in T1FHa and T1FHc and aaa in T1FHb). Intermediate ratios are indicated by intermediate colors. Blue shade represents
more copies of “a” alleles (e.g., aab on the central trisomic region of ChrR in T1FHb), and purple shade represents more copies
of the “b” alleles (e.g., abb on Chr7 in all three clones). The portion of ChrR in clone T1FHb to the right of the rDNA region
(blue dot) is present in ﬁve copies. Major repeat sequences are represented by black dots.
Mistranslation Hastens Evolution of Drug Resistance
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by copy number variation in T1FH showed increased usage of UCA and lower usage of
UCC and UCG than the rest of the genome. Notably, the balancing effect of CUG codon
usage observed for LOH was also detectable for copy number variation (Table S2).
To gain deeper insight into the segmental aneuploidies, we performed single
nucleotide polymorphism (SNP)-CGH analysis of three T1FH clones (Fig. 2). Our CGH
analysis suggested that all of our clones were nearly tetraploid, with Chr7 being
trisomic. It appears that either the b homolog reduplicated or one copy of the a
homolog was lost, leading to the Chr7 abb trisomy in T1FH (Fig. 2). One of the T1FH
clones (T1FHb) was also trisomic (aaa) for the common LOH region of ChrR for which
the other two clones were tetraploid (aaaa). In the T1FHb clone, the LOH region (aaa)
of ChrR was followed by an additional trisomic LOH region (abb) (Fig. 2). Another
feature of this clone was the copy number losses that appeared to the right of the rDNA
locus of ChrR. WGS showed that during evolution in the drug, T1FM increased the copy
number of the rDNA locus, albeit transiently, as the chromosomal ampliﬁcations
disappeared in the highly resistant T1FH strain. Thus, our results support the observa-
tions that the rDNA locus is a fragile site that can cause copy number variation on
chromosome ends (25, 26) and additionally might be relevant for a rapid adaptation to
ﬂuconazole.
Gene expression deregulation induced by mistranslation. Comparing the gene
expression patterns of all of the strains and conditions used in this study revealed that
during evolution in the drug, strain T0 showed a ﬂuconazole-induced stress response,
while strain T1 upregulated several mating-related genes, as well as genes encoding
sugar transporters (Fig. 3). To distinguish the effects of adaptation to ﬂuconazole from
the effects of mistranslation, we compared the mRNA expression patterns of the
hypermistranslating T1 strain that evolved in the presence (T1FH) and absence of the
drug (T1NF) (Fig. S5). Gene set enrichment analysis (GSEA) (27) of T1FN detected
deregulation of expression of translation genes, including those involved in tRNA and
rRNA processing, tRNA methylation and modiﬁcation, mRNA splicing, cytosolic and
mitochondrial ribosomal subunit biosynthesis, and ribosomal biogenesis and assembly
(Fig. S5). In T1FH, treatment with ﬂuconazole resulted in downregulation of genes
related to ribosome biogenesis, e.g., those required for maturation of large-subunit
rRNA genes (Fig. S5). These GSEA results suggest that the hypermistranslating strain
(T1) evolved in the absence of ﬂuconazole had remodeled tRNA and rRNA processing
and that addition of ﬂuconazole repressed protein synthesis (Fig. S5). Mistranslation
also upregulated genes involved in organic acid and amino acid metabolic processes
and downregulated genes involved in glycoside and carbohydrate metabolic pro-
cesses, cellular iron homeostasis, oxidation-reduction processes, and glycolysis (Fig. S6).
The FMP45 gene, which is involved in sensitivity to toxic ergosterol analogs and is
induced during mating, was downregulated during evolution of the hypermistranslat-
ing T1 strain in the absence of ﬂuconazole (T1NF) but upregulated in the presence of
the drug (T1FH) (Fig. S6), suggesting that FMP45 may also play a role in ﬂuconazole
resistance.
Mating and cell surface alterations. WGS and CGH also showed that T1 lost the
MTLa locus (including the nonsex genes PAP1, PIKa, and OBPa) during evolution in
ﬂuconazole (Fig. 2 and 4; Fig. S7) and increased the copy number of several genes on
Chr7 involved in mating, transport, and translation, including orf19.6583, orf19.7038,
FLU1, WHI3, TOM70, NBP2, YCF1, and GCN2 (Table 1).
In addition to those genome alterations, in T1FH, we observed a 6.5-fold increase in
the expression of MFalpha, the alpha factor mating pheromone gene, and a gene set
enrichment of mating-speciﬁc terms like bud neck and ascospore formation,
pheromone-dependent transcription involved in conjugation with cellular fusion, and
terms related to virulence, like adhesion to a host and immune response (Fig. 3; Fig. S6).
These gene expression alterations in T1FH are possibly related to loss of the MTLa locus
and/or the LOH of Chr5 (28–30).
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DISCUSSION
Mistranslation is linked to elevated mutagenesis and the appearance of drug
resistance in bacteria (17, 31), but its role in eukaryotes is still poorly understood. In this
study, we used experimental evolution to examine the ability of a C. albicans strain that
mistranslates at high levels to acquire resistance to ﬂuconazole. By comparing changes
in a hypermistranslating strain with those in a WT strain subjected to or excluded from
ﬂuconazole treatment, we could detect contributions of mistranslation to drug resis-
tance at both the genome and transcription levels. During evolution in the absence of
ﬂuconazole, the resistance to ﬂuconazole of both the WT T0 and hypermistranslating T1
strains was similar. In contrast, strain T1 became resistant to ﬂuconazole at a much
earlier time point during evolution in the drug. Our data suggest that different ways of
upregulating drug efﬂux pumps, together with genomic changes in drug target genes,
may speed up the acquisition of resistance in mistranslating strains. Increased drug
efﬂux in the T0FM strain was likely mediated via the multidrug efﬂux pump encoded by
MDR1, while T1FM overexpressed the ABC superfamily transporter genes CDR1 and
CDR2. Additionally, in T1FM, ERG11, the gene encoding the ﬂuconazole target protein,
became homozygous. An elevated copy number of the FLU1 gene and the open
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FIG 3 Gene expression heatmap. Depicted are DEGs with a 4-log-fold change for at least one
comparison and a false discovery rate-adjusted P value of 1e18.
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reading frame for a putative multidrug resistance protein (orf19.3218) may also have
contributed to ﬂuconazole resistance in T1.
Recent literature suggests that a common mechanism for the acquisition of drug
resistance involves LOH, which is often accompanied by aneuploidy (11). In T1FH, the
two major LOH regions of ChrR and Chr5 include a large proportion of genes involved
in both translation and drug resistance. This suggests that allele-speciﬁc gene functions
may contribute to rapid adaptation to azoles and/or to stabilization of the mistransla-
tion state and that CTG codon usage seems to have a balancing effect on such genomic
events (Table S2). Further, the tRNA aminoacylation system might be a driving force for
the LOH in hypermistranslators.
Interestingly, mistranslation led to both upregulation of amino acid metabolism and
mutations in tRNA synthetases (T1NF), with the latter being increased under drug
pressure (T1FH). For example, PIKa encodes a phosphatidylinositol kinase and is located
within theMTLa locus that was lost on Chr5. While ΔMTLa1 ΔMTLa2 allows growth even
in the highest levels of ﬂuconazole (32), ΔPIKa may play a role in translation initiation.
In Saccharomyces cerevisiae conditional mutants of the PIKa ortholog, Pik1 controls
translation initiation independently of TOR (33). S. cerevisiae Pik1 mutation leads to a
4-fold increase in the phosphorylation of translation initiation factor 2 alpha (elf2).
Further, the general amino acid control (GCN) response induces the amino acid
FIG 4 Highlighted features of quickly evolving and highly resistant strain T1. Mistranslation appears to affect the phosphatidylinositol signal transduction
pathways that control several cell cycle events, cell membrane and cell wall remodeling, as well as protein synthesis and turnover, via GCN2, most of which
are known to enhance drug resistance. The main features of highly drug-resistant strain T1FH are depicted, i.e., loss of MTLa and the nonsex gene PIKa;
phosphatidylinositol signaling and downstream targets such as DNA repair, cell wall remodeling, and mating; GCN2-mediated modulation of protein synthesis;
drug efﬂux pumps; and bud neck formation.
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biosynthesis pathways upon the accumulation of uncharged tRNAs (34, 35). The
increase in the copy number of elf2 kinase GCN2 observed in the T1FH strain suggests
that high levels of elf2 phosphorylation could be a speciﬁc translational modiﬁcation
required for adaptation to ﬂuconazole.
Another feature that appeared in T1 during drug resistance evolution was the
accumulation of a large number of SNPs and codon changes in the PGA, IFF, and ALS
genes, which encode glycosyl-phosphatidylinositol (GPI)-anchored proteins. Addition-
ally, the AGM1 gene, which is involved in the chitin biosynthetic pathway (synthesis of
UDP-N-acetylglucosamine), was speciﬁcally upregulated in evolved T1 strains (Fig. S3).
N-Acetylglucosamine is a moiety of the synthesis of GPI anchors and a building block
of chitin (36). Sequences encoding GPI-anchored adhesins are rich in CUG codons, and
a recent study demonstrated that CUG mistranslation enhances the ability of C. albicans
to adhere to different surfaces, especially under stress conditions (37). Remodeling of
the cell wall and modiﬁcation of adhesion properties are important features of drug
resistance and virulence (38, 39). Consistent with this, T1FH ﬂocculated and showed
strong adhesion to surfaces in liquid medium (data not shown). Hence, by expanding
the variability of cell wall proteins, CUG codon ambiguity could allow C. albicans to
accelerate the acquisition of antifungal resistance.
TABLE 1 Copy number variation in T1FHa
aGenes that revealed high concordance in copy number changes in both SNP-CGH and
WGS analysis are shown. Apart from the MTL genes that were also lost in T1FM, all of
the gene alterations listed appeared exclusively in strain T1FH. Colors: red, copy
number gain; blue, copy number loss. Increasing color intensity reﬂects an increase in
gain or loss, respectively.
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Several serine/threonine kinases and serine/threonine phosphatases lost heterozygosity
and/or changed gene expression levels in T1FH. Here, overexpression of the SHA3 gene,
encoding a Ser/Thr kinase, which regulates glucose transport, is likely responsible for the
upregulation of sugar import genes in the resistant T1FH strain. Members of the
transporter-encoding HGT and HXT gene families were also overexpressed. As the genes
regulating the ﬁrst steps of glycolysis (PGI1, PFK1, and PFK2) were downregulated and INO1,
which encodes the key enzyme of myo-inositol biosynthesis, was upregulated, we assume
that the imported glucose is channeled into myo-inositol biosynthesis in T1FH, which is
essential for growth and virulence in C. albicans (40). Additionally, theMec1 gene, which
is located on the right arm of Chr5, was one of the few genes that were highly enriched
in LOH events (Mec1, 60 [median, 5] LOH events) exclusively in T1 strains exposed to
ﬂuconazole. Mec1 is a serine threonine- and leucine-rich putative phosphatidylinositol
kinase that, upon DNA damage, phosphorylates a large set of proteins, and together
with its yeast ortholog, Mec1 was repeatedly linked to genome instability, telomere
maintenance, and drug response (3, 41, 42). Flow cytometry (Fig. S7) suggested that
T1FH cells have multiple ploidy states, including diploids, tetraploids, and a smaller
population of cells with 4c ploidy. Alterations in ploidy were recently shown to occur
soon after C. albicans cells are exposed to ﬂuconazole, and it is thought that they
provide the ﬁrst step in the formation of aneuploid cells with a wide range of
phenotypic variability (43).
Taken together, our data suggest that mistranslation mediated more rapid evolution
of ﬂuconazole resistance via a range of mechanisms, including the classical effects on
efﬂux and ergosterol biosynthesis, among others. Dissection of the genes necessary
and sufﬁcient for this evolution will require additional studies. In particular, parallel
evolution of multiple clones of both hypermistranslating and WT strains is necessary to
clarify the adaptive and mechanistic relevance of the multiple and important mutations
identiﬁed in this study. Our data leave no doubt that mistranslation accelerates the
evolution of resistance to ﬂuconazole in C. albicans; whether mistranslation is a major
driver of mutagenesis in drug stress will be fascinating to study in future work.
MATERIALS AND METHODS
Strains and growth conditions. The C. albicans strains used in this study were engineered to exhibit
different levels of leucine misincorporation at serine CUG codons. The T0 control strain incorporates 3.2%
Leu and 96.8% Ser at CUG codons (normal level of mistranslation in C. albicans); T1 incorporates 22.5%
Leu and 77.5% Ser at CUG codons (16). All strains were constructed with the SN148 parental strain
(arg4Δ/arg4Δ leu2Δ/leu2Δ his1Δ/his1Δ ura3Δ::imm43/ura3Δ::imm43 iro1Δ::imm43/iro1Δ::imm43) (44) by
homologous recombination as described in reference 16.
Incorporation of Leu and Ser at CUG codons was determined with a previously developed gain-of-
function reporter (16). Fluorescence was quantiﬁed with a Zeiss MC80 Axioplan 2 light microscope
equipped for epiﬂuorescence microscopy with the HE38 ﬁlter set (Carl Zeiss AG). Images were taken with
an AxioCam HRc camera and analyzed with ImageJ software (https://imagej.nih.gov/ij/) as previously
described (16).
Strains were grown in synthetic deﬁned (SD) medium without uracil containing 0.67% yeast nitrogen
base, 2% glucose, and 0.2% dropout mix (with 2% agar for solid medium only) at 30°C.
Experimental evolution. Resistance to ﬂuconazole was monitored by the E-test method (AB Biodisk,
BioMérieux). Cells were grown to mid-log phase, washed in 1 phosphate-buffered saline, and diluted
to an optical density at 600 nm of 0.015. A 150-l volume of cells was plated on SD minus uracil agar
plates (pH 7) with glass beads and allowed to dry for 15 to 30 min before a ﬂuconazole E-test strip (0.016
to 256 g/ml; AB Biodisk) was applied. Plates were incubated at 30°C for 48 h, and the MIC was
determined as the concentration at which the ﬁrst growth inhibition ellipse occurred. To perform the
evolution and E-test experiments in parallel, cells were incubated in liquid (SD minus uracil) medium
adjusted to 1 and 2 the last measured ﬂuconazole (Sigma-Aldrich) MIC. Depending on growth in the
respective concentrations of ﬂuconazole, passages were pursued until strains were able to grow in liquid
medium containing a ﬂuconazole concentration of 256 g/ml (Fig. S1). Additionally, control clones were
evolved for an equal number of passages without ﬂuconazole to study the effects of mistranslation and
the antifungal (T0NF and T1NF).
Nucleic acid extraction. RNA and DNA were extracted from strains at the beginning (T0 and T1),
middle (T0FM and T1FM), and end of evolution with ﬂuconazole (T0FH and T1FH) and from the evolved
control strains (T0NF and T1NF) (Fig. S1). Additionally, to test for clonal diversity, resistant strains were
grown in the highest concentration plated on SD minus uracil agar plates and three single colonies
(T1FHa to T1FHc) were picked for DNA extraction.
RNA was extracted from mid-exponential-phase cells by the hot phenol method. DNase I
(Invitrogen)-treated RNA was resuspended in RNase-free water, and RNA quantity and integrity were
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assessed by UV/Vis spectrometry (NanoDrop; Thermo Scientiﬁc) and with the Agilent 2100 Bioanalyzer,
respectively. Only RNAs with an integrity number of 9 were selected for further analysis.
DNA was extracted with the Genomic-tip 100/G kit (Qiagen) in accordance with the manufacturer’s
instructions. DNA was resuspended in EB buffer, and DNA quantity and integrity were assessed with the
Quant-iT PicoGreen double-stranded DNA quantitation assay and by agarose gel electrophoresis.
Transcriptome analysis. Custom gene expression SurePrint G3 microarrays (Agilent-065138) were
hybridized with CY3-labeled cRNA of growth duplicates in accordance with the manufacturer’s instruc-
tions (Agilent Low Input Quick Amp Labeling kit). Arrays were scanned on an Agilent G2505C microarray
scanner, and microarray scan data were extracted with Agilent feature extraction software.
Raw gene expression microarray data were normalized with limmaGUI software (R/Bioconductor,
Boston, MA) (45). Differentially expressed genes (DEGs) were extracted with limma (45) by using a
differential threshold of 1.5 and a false discovery rate-corrected P value of 0.05. Functional enrichment
was performed with GSEA (27) based on GO terms. Strains evolved in the presence of ﬂuconazole (TxFM,
TxFH) were initially compared to the respective untreated and nonevolved strain (Tx). Additionally, TxFH
strains were compared among themselves and against the respective control strain (TxNF). For each
comparison, GO sets with 15 and 500 annotated genes were selected as enriched if the corrected
P value was0.01 (1,000 gene set permutations). Enriched sets were related upon shared genes with the
Cytoscape plugin EnrichmentMap (46). Figure 3 was generated with the R package pheatmap (47).
Voronto software (48) was used for visualization of gene expression on the basis of GO biological process
(BP) categories (Fig. S3).
Whole-genome resequencing. One paired-end library was prepared for each sample in accordance
with Illumina DNA sample preparation protocols. Libraries were sequenced with the Illumina genome
analyzer IIx.
Raw sequence data (101- and 146-bp paired-end reads) from eight samples (T0, T1, T0FM, T1FM,
T0FH, T1FH, T0NF, and T1NF) were initially trimmed by removing consecutive bases on both the 5= and
3= ﬂanks with base qualities of 20. Trimmed reads that did not pass the ﬁltering criteria for ambiguity
(N content of 5%), complexity (score of 10), length (50 bases or longer), and average base quality
(20) were removed with PRINSEQ (49).
Remaining reads were mapped to the reference genome of C. albicans obtained from the Candida
genome database (http://www.candidagenome.org/; assembly 21) with BWA version 0.6.2 (50). Process-
ing and ﬁltering of mapped reads were done with SAMtools version 0.1.17 (51). After removal of
duplicates, read pairs where both reads mapped on different chromosomes were removed. Additionally,
read pairs where one or both reads were not mapped or had low mapping quality (37) were removed.
The control strain used in this experiment, T0, is genetically slightly different from SC5314, which was
used to construct the reference genome. SAMtools was used to produce read pileups, detect single
nucleotide variants, and call genotypes. Indels were not called. Bases with a read depth of 5, a low
quality of REF/ALT polymorphism (20), low genotype quality (20), and low consensus quality (|20|)
were called as unknown genotype. Additionally, unknown genotypes were called if a base had more than
three allele types and the read depths of all of the allele types were 5.
For the eight samples, we analyzed genomic features (coding, noncoding, or repeat region, etc.) and
LOH of bases with different genotype compared with the control strain. Structural variations in coding
regions were also analyzed for changes in codon usage.
Copy number analysis was performed with CNAnorm (52). Aligned reads of each sample were split
into 2-kb windows, and reads were counted. CNAnorm was used to estimate copy numbers with
normalization of paired control and test samples.
SNP-CGH. SNP-CGH array analysis was performed with custom Agilent arrays (eArray Design ID
038464 [53]). Three T1FH clones (T1FHa to T1FHc) were compared with control strain T0. Genomic DNA
was digested with AluI and RsaI, ampliﬁed, labeled, and hybridized in accordance with the manufactur-
er’s instructions with the Agilent Genomic DNA enzymatic labeling kit (Agilent). Arrays were scanned on
an Agilent G2505C microarray scanner, and microarray scan data were extracted with Agilent feature
extraction software. All of the samples analyzed in this study passed the quality control performed with
the R/Bioconductor packages GLAD (positional biases) and arrayQualityMetrics (statistical distributions)
without any relevant issue (54, 55). Genomic events for SNP-CGH data were predicted by computing
hidden Markov model states via the R/Bioconductor SNP-CGH package (56) by using default parameters.
Genome ratios were plotted with the R/Bioconductor SNP-CGH package and mapped against C. albicans
chromosome annotations (http://www.candidagenome.org/; assembly 21). Allele fractions were calcu-
lated with a custom R script from the SNP probes in the SNP-CGH data.
Additionally, the data were visualized with YMAP (57). Therefore, the array data ﬁles produced during
extraction were uploaded into YMAP for processing by using the SNP-CGH array processing option with
the GC bias correction option selected to correct for artifacts in the array data caused by variations in
percent GC across the genome. After YMAP processed the data, it produced cartoon ﬁgures displaying
copy number and allelic ratio changes across the genome for each clone. See the legend to Fig. 2 for
details of how the data are presented and for interpretation of the data for each of the three clones
(T1FHa to T1FHc).
Accession number(s). The raw microarray data obtained in this study have been submitted to the
Gene Expression Omnibus and assigned GenBank accession numbers GSE60121 and GSE60122. The array
CGH data are listed in the Gene Expression Omnibus under GenBank accession number GSE60120.
Sequencing data were archived in ArrayExpress under accession number E-SYBR-13.
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